Abstract
In this paper we present study of metabolic control in children suffering from TYPE 1 Diabetes Mellitus (T1DM) who use insulin pump (IP) therapy, and who were treated at Paediatric Clinic in Sarajevo. In retrospective study we followed all T1DM patients with IP therapy introduced in the period from 1st March 2005 to 1st September 2008. We analyzed their age and sex structure, therapy before IP use, and the metabolic control of T1DM represented with glycosylated haemoglobin (HbA1c) value just before and 6 months after IP therapy introducing. The total number of observed patients was 39. There were 24 boys (61,5 %) and 15 girls (38,5 %) with the age range between 12,3 +/- 3,2 years. Most patients were from age group 8-14 years. In the same number of patients 17 (43,6 %) diabetes duration was less than 5 years and 5-10 years. Before IP introduction most patient 61,5 % use therapy with insulin analogues. Mean value of HbA1c before IP therapy introduction was 8,57+/-1,65 % and 6 months after IP therapy introduction HbA1c 7,53 +/- 0,81 % (p = 0,0009). There was significant reduction HbA1c values even 6 month after IP therapy introduced. Therapy with IP in children with diabetes was very efficient in achieving therapeutic goal of T1DM treatment (HbA1c<7,0 %) what will protect patients from appearance and progression of chronic micro vascular complications on eyes, kidneys and peripheral nerves.
Highlights
BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES 2009; 9 (2): 121-124 were established on the base of indications from leading Diabetes Associations and authors
All patients - years of age suffering from Diabetes Mellitus (T DM) and treated with insulin pump (IP) therapy at Paediatric Clinic in Sarajevo were observed in this study
This study represents retrospective analysis of metabolic control of children suffering from T DM in who was introduced IP insulin therapy in the period from the st March to the st September
Summary
BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES 2009; 9 (2): 121-124 were established on the base of indications from leading Diabetes Associations and authors. Those indications were originally fitted to our needs ( , ). Medical indications were: bad metabolic control of T DM (HbA c> , ), significantly elevated insulin autoantibody (> , ), early age of T DM beginning (age< years), duration of T DM (≥ years) and associated diseases. Other indications were: motivation for IP therapy, T DM in closest relative and bad life quality during previous treatment. Leading indications for IP introducing were significantly elevated insulin autoantibody, motivation for IP therapy and bad life quality.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
